EMMA
Emmaus Life Sciences Incorporation
Halal Rating :
Last Price
$7.76
Last updated:
Market Cap
-
7D Change
90132.56%
1 Year Change
7660.0%
Company Overview
Industries
Exchange
Next Earnings Date
Emmaus Life Sciences Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies and treatments for rare and orphan diseases. Their lead product is Endari® (L-glutamine oral powder), an FDA-approved treatment for sickle cell disease.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $5.48m | $6.11m | - | $1.46m | 0.00% | 23.81% |
| June 30, 2024 | $5.38m | $5.76m | - | $966000.0 | 0.00% | 16.77% |
| March 31, 2024 | $2.51m | $6.12m | - | $878000.0 | 0.00% | 14.34% |
Company Impact
Help us evaluate Emmaus Life Sciences Incorporation's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.